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We sought to examine the impact of asymptomatic
bacteriuria on renal transplant outcome by retrospectively
analyzing 189 renal transplant recipients for whom
systematic screening uncovered 298 episodes of
asymptomatic bacteriuria in 96 recipients. These patients
were treated and all were followed for 36 months. Significant
risk factors included female gender, glomerulonephritis as
the disease that led to transplantation, and double renal
transplant. There were no differences in serum creatinine,
creatinine clearance, or proteinuria between patients with
and without bacteriuria. The incidence of pyelonephritis in
these patients was 7.6 episodes per 100 patient-years
compared with 1.07 in those without asymptomatic
bacteriuria. Between two to five and more than five
bacteriuria episodes were significant independent factors
associated with pyelonephritis whereas more than five
episodes was a significant independent factor associated
with rejection. Thus, we found no differences in renal
function prognosis between patients who do not develop
asymptomatic bacteriuria and those uncovered by systematic
screening and who received treatment following kidney
transplantation. Despite this treatment, the incidence
of pyelonephritis was much higher in the group
of patients with detected asymptomatic bacteriuria.
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Renal transplantation is the best option for terminal renal
insufficiency. In spite of advances in prophylaxis and
treatment, infection remains a major cause of morbidity
and mortality in this population.1 Urinary tract infections
(UTIs), including asymptomatic bacteriuria, cystitis, and
pyelonephritis, are the most common form of bacterial
infection in renal transplant recipients.2–4 These infections
are thought to be directly attributable to the exposition of
pathogens during the early postoperative period and to
immunosuppressive therapy. UTI incidence after renal
transplantation has been reduced in recent decades because
of improvements in surgical procedures,5 early removal of
urethral catheters,6 and antibiotic prophylaxis, but it is still
higher than in the general population.
The clinical impact of asymptomatic bacteriuria has been
extensively studied in different populations such as diabetic
patients, patients pending of urological intervention, preg-
nant women, and the elderly population. Screening for and
treatment of asymptomatic bacteriuria are well established
before transurethral resection of the prostate (or before other
urological procedures in which mucosal bleeding is antici-
pated) and for pregnant women (recommendation strength
grade A-I).7 Asymptomatic bacteriuria screening and treat-
ment have not been thoroughly evaluated for solid organ
recipients, and hence recommendation strength of present
guidelines is grade C-III.7
In this study we evaluate the role of systematic asympto-
matic bacteriuria screening and treatment in the first 3 years
after renal transplantation and their impact on pyelonephritis
incidence and renal allograft function.
RESULTS
Patients included
Between January 2002 and December 2004, 235 patients
received a renal transplant at our institution. A total of 46
patients (19.57%) were excluded from the present study
because of incomplete clinical history (25 patients), survival
of renal graft for o30 days (12 patients), survival for o30
days (2 patients), and loss of follow-up (7 patients). Finally,
189 patients were included in the cohort and all of them were
followed-up for 36 months. The population characteristics
are summarized in Table 1. During follow-up, only one
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patient died and another required transplant nephrectomy.
Appointment date was respected in 98% of the occasions.
Urine sample was correctly collected at every medical visit. In
90 of 298 episodes of asymptomatic bacteriuria (30%),
antibiotic treatment was not administered. There were no
reported cases in which more than one consecutive episode of
asymptomatic bacteriuria was not treated with antibiotics.
Development of asymptomatic bacteriuria
Among 189 renal transplant recipients, 96 (50.79%) patients
presented 298 episodes of asymptomatic bacteriuria (one
episode in 36, between two and five episodes in 45, and more
than five episodes in 15 patients) and 93 did not experience
any episode of asymptomatic bacteriuria, throughout the 36
months of follow-up. Escherichia coli was the most frequently
isolated bacteria (58.3% of the episodes), followed by
Enterococcus faecalis (11.8%), Klebsiella pneumoniae (9.3%),
and Streptococcus agalactiae (5.2%). Table 2 contains the
complete list of isolated microorganisms. In 152 of the 298
episodes of asymptomatic bacteriuria (51%), the isolated
bacteria were trimethoprim-sulfamethoxazole resistant.
No major adverse effects were recorded related to antibiotic
administration for asymptomatic bacteriuria treatment.
The time pattern of the different types of UTI episodes is
shown in Figure 1. Asymptomatic bacteriuria episodes
occurred all through the 36 months of follow-up, but mostly
in the first 12 months. Most of pyelonephritis episodes
occurred in the first year after transplantation.
Asymptomatic bacteriuria-associated risk factors
Risk factors for the development of asymptomatic bacteriuria
are analyzed in Table 3. The variables that were independently
related to the development of asymptomatic bacteriuria in
the final multivariate model were female sex of the recipient
(odds ratio (OR) 4.397; confidence interval 2.307–8.379;
P¼ 0.0001), glomerulonephritis as the disease that led to
transplantation (OR 2.075; confidence interval 1.001–4.302;
P¼ 0.0497), and double renal transplant (OR 4.011;
confidence interval 1.68–13.775; P¼ 0.0273).
Long-term influence of asymptomatic bacteriuria on renal
graft function
We found no significant differences in serum creatinine,
creatinine clearance, or proteinuria throughout the 36
months of follow-up between those patients who developed
asymptomatic bacteriuria and those who did not (Figure 2).
Patients were arbitrarily classified into four groups according
to the number of asymptomatic bacteriuria episodes during
follow-up: no episode (93 patients), 1 episode (36 patients),
2–5 episodes (45 patients), and 45 episodes (15 patients).
No differences in renal function (assessed by serum
creatinine, creatinine clearance, and proteinuria) were found
when the number of asymptomatic bacteriuria episodes was
taken into account. Asymptomatic bacteriuria influence on
survival of both the allograft and the patient was impossible
to calculate as only one patient died and only one lost the
graft during follow-up.
Table 1 | Clinical characteristics of the 189 patients included
in the study
Description No. (%)
Female 75 (39.68%)
Male 114 (60.32%)
Transplant number 189 (100%)
Recipient age Mean 49 years, range:
20–78 years
Pretransplant serological status:
Cytomegalovirus, IgG positive 169 (89.42%)
Virus hepatitis B, Ag core positive 26 (13.76%)
Virus hepatitis C, IgG positive 16 (8.47%)
Virus hepatitis C, RNA positive 11 (5.82%)
Transplantation characteristics:
Cadaveric donor 189 (100%)
First renal transplant 168 (88.89%)
Second renal transplant 21 (11.11%)
Single renal transplant 169 (89.42 %)
Double renal transplant 18 (9.52%)
Simultaneous renal–pancreas transplant 1 (0.53%)
Simultaneous renal–hepatic transplant 1 (0.53 %)
Etiology of renal failure before transplantation
Glomerulonephritis 46 (24.34%)
Chronic interstitial nephropathy 28 (14.81%)
Diabetic nephropathy 26 (13.76%)
Nephroangiosclerosis 22 (11.64%)
Congenital nephropathy 4 (2.12%)
Polycystic kidney disease 20 (10.58%)
Unknown 36 (19.05%)
Othersa 7 (3.70%)
Post-transplant cytomegalovirus disease 17 (8.99%)
Post-transplant antibiotic prophylaxis with
cotrimoxazol (3 months)
189 (100%)
Urinary tract surgery after transplantation 32 (16.93%)
Abbreviations: Ag, antigen; IgG, immunoglobulin G; RNA, ribonucleic acid.
aSo¨jgren syndrome, systemic lupus erythematosus, and amyloidosis.
Table 2 | Frequency of microorganisms isolated in urine
culture in asymptomatic bacteriuria episodes
Bacterium
Frequency
(no.)
Percentage
(%)
Escherichia coli 200 58.31
Enterococcus faecalis 38 11.08
Klebsiella pneumoniae 32 9.33
Streptococcus agalactiae 18 5.25
Proteus mirabilis 12 3.50
Staphylococcus epidermidis 8 2.33
Pseudomonas aeruginosa 7 2.04
Morganella morganii 6 1.75
Klebsiella oxytoca 5 1.46
Enterococcus faecium 5 1.46
Acinetobacter baumannii 2 0.58
Citrobacter freundii 2 0.58
Streptococcus viridans 2 0.58
Enterobacter cloacae 2 0.58
Stenotrophomonas maltophila 2 0.58
Corynebacterium striatum 1 0.29
Streptococcus gordonii 1 0.29
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Relationship between asymptomatic bacteriuria and
rejection
An analysis was made to establish risk factors for organ
rejection (Table 4). The presence of one or more asympto-
matic bacteriuria episodes was significantly correlated with
rejection development in univariate analysis. Only the
presence of45 asymptomatic bacteriuria episodes remained
as an independent factor associated with rejection in
multivariate analysis (OR 3.46; Po0.03; Table 4).
Relationship between asymptomatic bacteriuria and cystitis
During follow-up, the total amount of cystitis episodes
diagnosed was 23 in the 189 subjects of the cohort: 19
episodes in 19 patients with asymptomatic bacteriuria
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Figure 1 | Time pattern of asymptomatic bacteriuria, cystitis, and pyelonephritis episodes throughout the 36 months of follow-up
(expressed as percentage of total number of episodes for each category).
Table 3 | Univariate and multivariate analyses of risk factors for asymptomatic bacteriuria development among the 189 renal
transplant recipients of the cohort
Univariate analysis Multivariate analysis
Variable OR 95% CI P-value OR 95% CI P-value
Age (460) 0.95 0.49–1.86 0.90
Female sex 2.51 1.35–4.70 o0.0001 4.39 2.30–8.37 0.0001
HCV infection 0.52 0.26–2.06 0.55
Kidney disease before Tx:
Glomerulonephritis 1.93 0.97–3.83 0.058 2.07 1.00–4.30 0.049
Chronic interstitial nephropathy 1.91 0.83–4.40 0.12
Diabetic nephropathy 0.96 0.42–2.20 0.93
Nephroangiosclerosis 0.77 0.30–1.95 0.58
Congenital nephropathy 0.31 0.03–3.09 0.32
Kidney polycystosis 0.77 0.30–1.95 0.58
Non-filiated kidney disease 0.63 0.30–1.32 0.22
Double transplant 2.87 0.88–9.39 0.079 4.01 1.16–13.77 0.027
First renal transplant 0.75 0.30–1.87 0.53
Second renal transplant 1.68 0.48–4.84 0.33
Urinary tract surgery after Tx 2.08 0.94–4.61 0.06
Nephrostomy after Tx 1.37 0.52–3.58 0.51
Cytomegalovirus disease after Tx 2.51 0.84–7.43 0.09
Abbreviations: CI, confidence interval; HCV, hepatitis C virus; OR, odds ratio; Tx, renal transplantation.
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episodes and 4 episodes in 4 patients without asymptomatic
bacteriuria episodes. All the cystitis episodes resolved
uneventfully under antibiotic treatment.
Relationship between asymptomatic bacteriuria and
pyelonephritis
The total amount of pyelonephritis episodes diagnosed was
25 in the 189 subjects of the cohort (global incidence of 4.4
episodes per 100 patient-years): 22 episodes in 17 patients
with asymptomatic bacteriuria and 3 episodes in 2 patients
without asymptomatic bacteriuria. The relationship between
the asymptomatic bacteriuria episodes and the pyelonephritis
episodes was as follows: 8 episodes occurred in the first
fortnight after transplantation—when the asymptomatic
bacteriuria detection strategy was not yet effective; 3 of
the pyelonephritis episodes occurred in patients who had
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Figure 2 |Relationship between asymptomatic bacteriuria (AB) and renal function throughout the 36 months of follow-up.
This relationship was assessed by: (a) serum creatinine level (mg/dl); (b) creatinine clearance (ml/min); (c) level of proteinuria (g/l); and
(d) level of proteinuria (g per 24 h) throughout the 36 months of follow-up. ANOVA test for repeated measures. Dashed lines denote the s.d.
Table 4 | Univariate and multivariate analyses of factors associated with kidney allograft rejection
Univariate analysis Multivariate analysis
Variable OR 95% CI P-value OR 95% CI P-value
Age (460) 0.95 0.49–1.86 0.90
HCV infection 3.88 1.04–14.39 0.42
Kidney disease before Tx:
Glomerulonephritis 1.93 0.97–3.83 0.058 NS
Chronic interstitial nephropathy 1.05 0.83–4.40 0.12
Diabetic nephropathy 0.96 0.42–2.20 0.93
Nephroangiosclerosis 0.77 0.30–1.95 0.58
Congenital nephropathy 0.31 0.03–3.09 0.32
Kidney polycystosis 0.77 0.30–1.95 0.58
Non-filiated kidney disease 0.63 0.30–1.32 0.22
Double transplant 2.87 0.88–9.39 0.07 NS
First renal transplant 0.75 0.30–1.87 0.53
Second renal transplant 1.68 0.58–4.84 0.33
Urinary tract surgery after Tx 2.12 1.02–4.41 0.06 NS
Nephrostomy after Tx 1.37 0.52–3.58 0.51
Cytomegalovirus disease after Tx 2.51 0.84–7.53 0.09
45 Episodes of AB vs 0 22.74 3.89–32.86 0.0005 3.46 1.07–11.18 0.037
2–5 Episodes of AB vs 0 7.83 1.99–8.514 0.0021 1.30 0.52–3.24 NS
1 Episode of AB vs 0 1.68 0.99–2.54 0.019 1.25 0.46–3.38 NS
Abbreviations: AB, asymptomatic bacteriuria; CI, confidence interval; HCV, hepatitis C virus; NS, not significant; OR, odds ratio; Tx, renal transplantation.
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not presented previous asymptomatic bacteriuria episodes; in 11
cases, the routine urine culture performed for detection of
asymptomatic bacteriuria detection was sterile just before the
patient developed the pyelonephritis episode; in 2 episodes,
asymptomatic bacteriuria was detected and adequately treated
immediately before pyelonephritis development (in both cases
the asymptomatic bacteriuria episode and the subsequent
pyelonephritis episode were produced by E. coli with the same
antibiotic susceptibility pattern); in the 4 remaining cases of
pyelonephritis, the strategy was not correctly applied (in 2 cases
the patient refused the asymptomatic bacteriuria treatment and
in 2 cases the attending physician missed the asymptomatic
bacteriuria episode treatment). The microorganisms isolated in
these cases were Pseudomonas aeruginosa, E. faecium,Morganella
morgagni, and coagulase-negative Staphylococcus. In the four
cases, the same specie was isolated in the asymptomatic
bacteriuria episode and in the subsequent pyelonephritis
episode. The incidence of pyelonephritis was 7.6 episodes per
100 patient-years in patients presenting asymptomatic bacteri-
uria versus 1.07 episodes of pyelonephritis per 100 patient-years
in patients who did not. The risk factors for pyelonephritis are
analyzed in Table 5. The presence of one or more episodes
of asymptomatic bacteriuria was significantly correlated with
the development of pyelonephritis in univariate analysis. The
detection of 2–5 episodes of asymptomatic bacteriuria (OR 7.7;
Po0.01) or45 episodes of asymptomatic bacteriuria remained
as independent factors associated with pyelonephritis in multi-
variate analysis (OR 13.5; Po0.008; Table 5).
DISCUSSION
Systematic screening and treatment of asymptomatic bacteri-
uria has been related to a reduction in pyelonephritis rate
in pregnant women and in those subjects who undergo
transurethral prostate resection (level of evidence A-I for
both categories).7 On the other hand, asymptomatic bacteri-
uria treatment in diabetic women has not shown any
protective effect neither in the development of pyelonephritis
nor in the mortality rate or the progression to diabetic
complications such as nephropathy. Systematic screening for
asymptomatic bacteriuria is not recommended in this group
(level of evidence A-I).7 For renal transplant recipients there
is scarce information regarding the benefit of systematic
asymptomatic bacteriuria screening and treatment in terms
of reduction in pyelonephritis incidence or prevention of
allograft nephropathy development. Recent guidelines affirm
that it is not possible to make a recommendation for
systematic screening or treatment of asymptomatic bacteri-
uria in renal transplant recipients (level of evidence C-III)7
and no reference to asymptomatic bacteriuria is made in
recent guidelines for outpatient surveillance in renal
transplant recipients.8 Previous studies have focused their
attention on the influence of UTI as a whole on the prognosis
of renal transplant recipients3,4,9,10 rather than on the
influence of asymptomatic bacteriuria. There is no doubt
about the need for treatment of symptomatic UTI. The
controversy remains around the convenience of systematically
treating asymptomatic episodes. Some researchers11 have
recommended asymptomatic bacteriuria treatment based on
the possibility that UTI, even asymptomatic, could lead to renal
allograft scarring in the context of vesicoureteric reflux.
Only two previous studies have addressed the problem of
asymptomatic bacteriuria in renal transplant recipients.12,13
One of them was published in 197912 and included 65
patients in whom 59 episodes of asymptomatic bacteriuria
were detected. The follow-up of these patients was 14 months
after transplantation. The other study was published
in 198513 and included 281 patients in whom 177 episodes
of asymptomatic bacteriuria were detected. The follow-up of
these patients ranged between 1 month and 16 years. In
neither of these studies12,13 is the frequency of asymptomatic
bacteriuria screening specified, nor the parameters estab-
lished to evaluate renal function.
The protocol of our hospital for renal allograft recipient
management establishes that asymptomatic bacteriuria must
be systematically screened and treated for a long period after
transplantation. This gave us a unique opportunity to study
its effect on pyelonephritis development and on renal
function prognosis. To our knowledge, there are no previous
studies that have evaluated this effect.
We found some risk factors independently associated with
the development of asymptomatic bacteriuria in the patients
of the cohort: female sex, glomerulonephritis as the disease
Table 5 | Univariate and multivariate analyses of risk factors for pyelonephritis
Univariate analysis Multivariate analysis
Variable OR 95% CI P-value OR 95% CI P-value
1 AB episode 5.686 0.994–32.541 0.0508 — — NS
2–5 AB episodes 9.836 1.994–48.514 0.0050 7.703 1.429–41.509 0.0175
45 AB episodes 22.746 3.894–132.864 0.0005 13.516 1.975–92.496 0.0080
Glomerulonephritis 4.136 1.563–10.941 0.0042 4.474 1.426–14.034 0.0102
X1 Acute rejection 3.537 1.308–9.562 0.0128 3.524 1.075–11.558 0.0376
Simple renal transplant 0.194 0.064–0.591 0.0039 0.193 0.052–0.712 0.0135
Double renal transplant 3.855 1.092–13.601 0.0360 — — NS
Cotrimoxazol prophylaxis 1.179 1.018–1.365 0.0275 — — NS
X2 Urinary tract surgeries 3.384 1.215–9.425 0.0196 — — NS
Recurrent UTI 7.042 2.513–19.728 0.0002 — — NS
Relapsing UTI 4.376 1.634–11.720 0.0033 — — NS
Abbreviations: AB, asymptomatic bacteriuria; CI, confidence interval; NS, not significant; OR, odds ratio; UTI, urinary tract infection.
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that produced the renal failure that led to transplantation,
and double renal transplant. Female sex has been recognized
as a risk factor for UTI in general population.14 Glomer-
ulonephritis before transplantation was a risk factor for both
asymptomatic bacteriuria (Po0.05) and pyelonephritis
(Po0.01). The rationale for this not previously described
association is not clear. The role of immunocompromising
co-morbidities (that is, lupus or systemic vasculitis) or the
amount and duration of pre- and post-transplant immuno-
suppression in this subgroup of patients may be hypothe-
sized. A relationship between the use of azathioprine or
mycophenolate mofetil and the development of UTI has been
previously described.9,15,16 Double renal transplantation
implies the presence of more renal parenchyma and more
anastomosis in the urinary tract, which could increase the
risk of infection. Special surveillance must be kept on these
groups of patients taking into account the potential risk of
developing UTI.
There are no previous studies evaluating the repercussion
of asymptomatic bacteriuria on renal function prognosis in
patients with kidney transplants. Our study shows that when
asymptomatic bacteriuria is systematically screened and
treated during the first 36 months after renal transplantation,
renal function prognosis is similar to the group of patients
who do not present asymptomatic bacteriuria during follow-
up. When the number of asymptomatic bacteriuria episodes
was taken in consideration, no differences were found. The
retrospective character of the present study did not allow us
to determine the influence of untreated asymptomatic
bacteriuria in the renal allograft prognosis. Although this
scientific information is not available, we have decided
to keep the protocol of systematic screening and treatment of
asymptomatic bacteriuria after renal transplantation at our
hospital.
When UTI was considered as a whole (asymptomatic
bacteriuria plus cystitis plus pyelonephritis), adverse impact
on long-term graft function was not found, provided
that asymptomatic episodes were systematically treated (also
analyzed by analysis of variance (ANOVA) test for repeated
measures).
The relationship between asymptomatic bacteriuria and
rejection episodes was studied. We found that, even when
systematically treated, repetition of asymptomatic bacteriuria
episodes was an independent factor associated with rejection.
We could not determine causality of this relationship, as not
all the episodes of rejection were preceded by asymptomatic
bacteriuria episodes. Previous studies have found a clin-
ical15,17,18 and pathogenic19 relationship between pyelone-
phritis and rejection in kidney transplant recipients.15,17,18
In our study, pyelonephritis was significantly more frequent
in patients with asymptomatic bacteriuria episodes. This
association of events could justify the relationship found
between asymptomatic bacteriuria and rejection. From a
clinical point of view, it could be important to consider that
asymptomatic bacteriuria identifies a high-risk subgroup for
rejection development among kidney graft recipients.
The relationship between asymptomatic bacteriuria and
pyelonephritis was studied. We found that, even when
systematically treated, repeated asymptomatic bacteriuria
episodes were an independent factor associated with
pyelonephritis. In this relationship also we could not
determine causality. However, pyelonephritis incidence was
more than seven times higher in the group of patients who
presented asymptomatic bacteriuria (7.6 episodes per 100
patient-years)—even when systematically treated—than in
the group of patients without asymptomatic bacteriuria (1.07
episodes per 100 patient-years). Previous studies in renal
transplant recipients have reported a pyelonephritis incidence
of 8.8 episodes per 100 patient-years15 (when asymptomatic
bacteriuria was systematically treated during the first 3
months after transplantation) and between 1218 and 2620
episodes per 100 patient-years when asymptomatic bacter-
iuria was not screened or treated after transplantation. If
these results are compared with those of the present study,
treating asymptomatic bacteriuria could be an option for
lowering pyelonephritis incidence, although it will remain
higher than in the group of patients who do not develop
asymptomatic bacteriuria. Recent studies have found a worse
prognosis for renal transplant recipients who develop
pyelonephritis.19 This probable extra benefit of the strategy
of systematic screening and treatment of asymptomatic
bacteriuria is another argument to maintain this protocol
in the renal transplant program of our hospital.
The strengths of this study are the number of transplant
recipients that were followed up (in every case up for
36 months) and the fact that on every visit asymptomatic
bacteriuria was systematically screened. But there are also
some drawbacks that deserve specific consideration, mainly
because of the retrospective nature of the study. Not in every
case was the asymptomatic bacteriuria episode treated with
antibiotics. Nevertheless, the study target was the validation
of a strategy for the whole kidney transplant program of a
hospital, rather than the strategy for an individual patient.
The definition of relapse was based on the isolation of the
same bacterium with same resistance pattern, whereas
molecular analysis of the strains was not made. No major
adverse effects were recorded related to the antibiotic
administration but minor adverse effects were not system-
atically recorded for this study.
Our data suggest that there are no differences in renal
allograft prognosis between those who do not develop asy-
mptomatic bacteriuria and those who do develop asympto-
matic bacteriuria and are systematically treated. Moreover,
systematic treatment of asymptomatic bacteriuria may
reduce pyelonephritis incidence. Prospective studies compar-
ing treatment versus non-treatment of asymptomatic
bacteriuria and its influence on allograft prognosis or
pyelonephritis incidence should be undertaken.
MATERIALS AND METHODS
The study was carried out at the 12 de Octubre University Hospital
12, a 1300-bed teaching hospital in Madrid, Spain. The study was
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approved by the local ethics committee of the hospital. We
retrospectively selected all the patients who had received a renal
transplantation at our institution between 1 January 2002 and
31 December 2004. The follow-up period was 36 months for every
patient. A standard technique was used for the allograft implanta-
tion. A urethral catheter was inserted before transplantation and
systematically removed 3 to 4 days after surgery.
Immunosuppressive treatment
A single 250mg dose of intravenous prednisolone was given
intraoperatively at anesthesia induction and a 250mg dose at the
moment of reperfusion. After surgery, a 0.5mg/kg dose of pre-
dnisone was given daily and progressively tapered to a total dose of
5mg/day. Steroids were associated with a combination of tacrolimus
(dose was adjusted for a therapeutic range of 10–15 ng/ml in the
induction period and 5–10 ng/ml in maintenance) or cyclosporine
(dose was adjusted for a therapeutic range of 100–300 ng/ml in the
induction period and 50–200 ng/ml in maintenance) with myco-
phenolate mofetil (dose was adjusted for a therapeutic range of
2–4mg/ml) or azathioprine (1.5mg/kg every 24 h). Rapamycin (5mg
per 24 h) was used in some cases.
Definition of acute rejection
Acute rejection was suspected in the case of an elevation of serum
creatinine (without an evident alternative diagnosis) and diagnosed
by histological examination if possible. If biopsy was not technically
possible, ‘intended-to-treat’ episodes that respond to antirejection
therapy were also taken into account. Graft loss was defined as the
requirement for dialysis and/or loss of a functioning graft because of
death of the renal transplant recipient.
Treatment for acute rejection episodes
Intravenous corticosteroid boluses were administered for 5 con-
secutive days followed by antithymocytic globulin in the event of
corticosteroid resistance (manifested as the persistence or exacerba-
tion of elevated serum creatinine after the last bolus and the absence
of histological improvement).
Antibiotic prophylaxis
All the patients received 2 g of intravenous cefazolin intraoperatively.
Postoperative antibiotic prophylaxis consisted of 160/800mg of
trimethoprim–sulfamethoxazole administered three times a week for
the first 3–6 months to prevent Pneumocystis jiroveci pneumonia and
other infections. Ganciclovir or valganciclovir were administered as
prophylaxis or pre-emptive treatment for cytomegalovirus infection
according to the Spanish guidelines.21
Infectious disease definitions
Bacteriuria was defined as two consecutive voided urine specimens
with isolation of the same bacterial strain in quantitative counts
4105 colony-forming units (cfu/ml) in asymptomatic women. A
single, clean-catch voided urine specimen with one bacterial species
isolated in a quantitative count of 4105 cfu/ml defined asympto-
matic bacteriuria in men. A single catheterized urine specimen with
one bacterial species isolated in a quantitative count of4102 cfu/ml
identified bacteriuria in women or men. Asymptomatic bacteriuria
was defined by the presence of bacteriuria in the absence of any
symptoms of lower or upper UTI. Cystitis was defined by the
presence of bacteriuria and clinical manifestations as dysuria,
frequency, or urinary urgency in the absence of pyelonephritis
criteria. Pyelonephritis was defined by the simultaneous presence of
a urine bacteria count of more than 105 cfu/ml and/or bacteremia
and fever with one or more of the following four categories: lumbar
pain, over graft pain, chills, criteria for cystitis (bacteriuria and
clinical manifestations such as dysuria, frequent urination, or
urinary urgency).14 Reinfection was defined by a new episode of
infection with the isolation of a bacteria other than the one that
caused the previous infection or the same bacteria with different
antibiotic sensitivity pattern.22 Relapse was defined as the isolation
of the same microorganism that caused the preceding infection, with
the same antibiotic sensitivity pattern, in a urine culture obtained
X2 weeks after finishing the previous treatment. Recurrent infection
was defined as X3 UTI in a 12-month period.
Antibiotic treatment
According to the protocol, every episode of asymptomatic
bacteriuria should be treated with antibiotics. Every episode of
symptomatic UTI was treated with antibiotics. Asymptomatic
bacteriuria and cystitis were treated with an oral antibiotic for 5–7
days, according to the antibiotic susceptibility of the microorganism
isolated. The antibiotics recommended for asymptomatic bacter-
iuria treatment, in order of preference, were: ciprofloxacin 250mg
per 12 h for 3 days; cefuroxime 250mg per 12 h for 7 days;
amoxicillin–clavulanate 500–125 per 8 h for 7 days; and fosfomicin
3 g in a single dose and a repeated dose 72 h later In the event of
pyelonephritis, the antibiotic was administered intravenously,
according to the antibiotic susceptibility of the microorganism
isolated, until the patient was afebrile and then orally for a total of at
least 14 days.
Visiting schedule and monitoring of asymptomatic
bacteriuria
Asymptomatic bacteriuria was systematically investigated in every
patient over a 3-year follow-up period. A urine sample was
processed every fortnight in the first trimester after transplantation,
monthly between months 4 and 12, every 2 months between months
13 and 18, and every 3 months from months 19 to 36. In every visit,
the patient was clinically questioned, physically explored, and a
blood sample and a urine midstream specimen were obtained for
urine culture and determination of serum creatinine (mg/ml),
creatinine clearance (ml/min), and proteinuria (calculated both in
g/dl and g per 24 h). Samples were also taken in the event
of symptomatic UTI and blood cultures were drawn in the event of
fever. In every episode of asymptomatic bacteriuria, cystitis, or
pyelonephritis, a postreatment-control urine culture was performed
2 weeks later. Urological evaluation was carried out for patients who
developed a second episode of pyelonephritis. Long-term renal graft
function was evaluated by means of serum creatinine, creatinine
clearance, and proteinuria throughout follow-up.
Data analysis
Continuous variables were expressed as the mean (± s.d.) for those
values with a normal distribution and as the median (mostly for
those with a skewed distribution). Discrete variables were expressed
as percentages. Student’s unpaired t-test was used to compare
continuous variables, the Mann–Whitney U-test was used to
compare continuous variables with non-normal distribution, and
the w2 or Fisher’s exact test was used to compare proportions. All
statistical tests were two tailed and the threshold of statistical
significance was Po0.05. ORs were calculated for variables with
statistically significant differences between patients with or without
asymptomatic bacteriuria. Binary logistic regression was applied
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individually to each variable to obtain the OR in the univariate
analysis. Statistically significant variables (Po0.05) in the univariate
analysis were introduced in a multivariate model by the use of
forward stepwise logistic regression, to identify the independent risk
factors for asymptomatic bacteriuria. Additionally, those factors
with P-values o0.1 that were considered clinically relevant
were forced in the multivariate model to investigate their effect.
Long-term repercussion of asymptomatic bacteriuria in the renal
graft function, determined as evolutive tendencies of serum
creatinine, creatinine clearance, and proteinuria, was assessed by
variance analysis (two-way ANOVA test for repeated measures).
Using a standard ANOVA in this case is not appropriate because it
fails to model the correlation between the repeated measures: the
data violate the ANOVA assumption of independence. ANOVA test
was used for comparing the means in creatinine, creatinine
clearance, and proteinuria between the groups of patients who did
or not did develop asymptomatic bacteriuria episodes throughout
the follow-up period. The SPSS statistical software, version 13.0
(Chicago, IL, USA), was used for performing calculations.
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